First Wave BioPharma, Inc.

Equities

FWBI

US33749P4081

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
2.96 ^USD	+4.59%		+6.47%	-29.52%

May. 10	First Wave BioPharma, Inc. announced a financing transaction	CI
Mar. 29	First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

First Wave Biopharma, Inc Announces Resignation from the Board of Directors

June 17, 2022 at 05:01 pm EDT

On June 16, 2022, Gregory Oakes submitted his resignation from the Board of Directors of First Wave BioPharma, Inc, effective immediately. Mr. Oakes indicated that his resignation was not the result of any disagreement with the Company on any matters relating to the Company's operations, policies or practices.

Latest news about First Wave BioPharma, Inc.

First Wave BioPharma, Inc. announced a financing transaction	May. 09	CI
First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Sector Update: Health Care Stocks Retreating Late Afternoon	Mar. 14	MT
Sector Update: Health Care	Mar. 14	MT
First Wave BioPharma Shares Fall After Acquiring ImmunogenX	Mar. 14	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Inflation Data	Mar. 14	MT
First Wave Biopharma, Inc. Announces Management Changes	Mar. 14	CI
First Wave BioPharma, Inc. completed the acquisition of ImmunogenX, LLC for $57.9 million.	Mar. 12	CI
Top Premarket Gainers	Jan. 03	MT
Wall St ticks up, S&P 500 near all-time closing high	Dec. 27	RE
Sector Update: Health Care Stocks Gain Late Afternoon	Dec. 27	MT
First Wave BioPharma Investors Exercise Warrants at Reduced Price -- Shares Up	Dec. 27	MT
Wall St wavers as S&P 500 hovers near all-time closing high	Dec. 27	RE
Sector Update: Health Care Stocks Higher Wednesday Afternoon	Dec. 27	MT
Sector Update: Health Care	Dec. 27	MT
Wall Street rises, S&P close to all-time high	Dec. 27	RE
Traders Look Ahead to Flat Day After Post-Christmas Rally	Dec. 27	MT
US Stock Market Futures Sluggish Following Holiday Gains	Dec. 27	MT
Top Midday Gainers	Dec. 27	MT
Top Premarket Gainers	Dec. 27	MT
First Wave BioPharma Shares Skyrocket After Selling Prospective Treatment for Inflammatory Bowel Diseases	Dec. 27	MT
First Wave BioPharma, Inc. signed a non-binding term sheet to acquire ImmunogenX, LLC.	Dec. 17	CI
First Wave BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
First Wave BioPharma Files for Secondary Offering of Shares	23-09-22	MT
Top Midday Gainers	23-09-14	MT

Chart First Wave BioPharma, Inc.

Duration

Period

More charts

Company Profile

First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency, and Capeserod, a selective 5-HT4 receptor partial agonist which the Company is developing as a gastroparesis therapeutic.

Sector

Biotechnology & Medical Research

Calendar

2024-05-19 - Digestive Disease Week Conference - A Composite Mucosal Scale for Celiac Disease

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.83 USD

Average target price

36 USD

Spread / Average Target

+1,172.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
FIRST WAVE BIOPHARMA, INC.	-29.52%	5.73M
MODERNA, INC.	+33.37%	49.46B
IQVIA HOLDINGS INC.	+1.55%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	18.64B
BIO-TECHNE CORPORATION	+7.36%	13.16B
MEDPACE HOLDINGS, INC.	+28.30%	12.55B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.1B

Other Biotechnology & Medical Research